Titan Pharmaceuticals, Inc.
TTNP
$4.99
$0.091.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -100.00% | -98.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -100.00% | -98.99% |
| Cost of Revenue | -- | -- | -- | -83.03% | -73.03% |
| Gross Profit | -- | -- | -- | 81.01% | 69.57% |
| SG&A Expenses | -58.04% | -25.09% | -17.86% | -1.08% | 11.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -63.40% | -40.15% | -38.93% | -29.54% | -20.18% |
| Operating Income | 63.37% | 39.36% | 37.38% | 26.83% | 16.51% |
| Income Before Tax | 48.64% | 15.04% | 15.50% | 4.53% | 35.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.64% | 15.04% | 15.50% | 4.53% | 35.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.64% | 15.04% | 15.50% | 4.53% | 35.49% |
| EBIT | 63.37% | 39.36% | 37.38% | 26.83% | 16.51% |
| EBITDA | 63.23% | 38.77% | 36.47% | 25.49% | 15.18% |
| EPS Basic | 55.07% | 28.20% | 29.32% | 15.86% | 42.42% |
| Normalized Basic EPS | 66.83% | 47.38% | 46.28% | 33.88% | 22.01% |
| EPS Diluted | 55.07% | 28.20% | 29.32% | 15.86% | 42.42% |
| Normalized Diluted EPS | 66.83% | 47.38% | 46.28% | 33.88% | 22.01% |
| Average Basic Shares Outstanding | 16.32% | 17.56% | 19.51% | 15.05% | 10.32% |
| Average Diluted Shares Outstanding | 16.32% | 17.56% | 19.51% | 15.05% | 10.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |